clinical trial · NCT01158157
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
Emergent BioSolutions·phase3·completed·n = 25
Smallpox Vaccine Adverse ReactionACAM2000
brief summary
The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
started
Sep 13, 2010
primary completion
Feb 14, 2012
completion
Feb 14, 2012
last updated
Mar 18, 2024
official title
Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol